Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ESRRG | P62508 | 2/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | SLC13A5 | Q86YT5 | 2/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.41 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17023799 | 0.94 | KCNH2 (0.61) | KCNH2SIGMAR1LMNAESRRGNR1H4 | |
| SCHEMBL8955876 | 0.86 | KCNH2 (0.52) | KCNH2SIGMAR1LMNAESRRGGRIA4 | |
| SCHEMBL31573982 | 0.86 | KCNH2 (0.67) | KCNH2SIGMAR1LMNAESRRGNR1H4 | |
| SCHEMBL7456580 | 0.81 | KCNH2 (0.59) | KCNH2SIGMAR1LMNAESRRGGRIA4 | |
| SCHEMBL28709923 | 0.81 | MAOB (0.40) | LMNATSHR | |
| SCHEMBL547838 | 0.80 | KCNH2 (0.60) | KCNH2SIGMAR1LMNAESRRG | |
| SCHEMBL14354808 | 0.78 | HTR1D (0.36) | KCNH2SIGMAR1 | |
| SCHEMBL1219727 | 0.78 | KCNH2 (0.58) | KCNH2SIGMAR1LMNAESRRGNR1H4 | |
| SCHEMBL1611687 | 0.78 | KCNH2 (0.58) | KCNH2SIGMAR1LMNAESRRGNR1H4 | |
| SCHEMBL21313315 | 0.78 | KCNH2 (0.63) | KCNH2SIGMAR1LMNAESRRGNR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10004701-B2 | Methods and compositions for treating infection | UNIVERSITY OF ROCHESTER (US) | 2018-06-26 | — | — | US | disclosed |
| US-10004701-B2 | Methods and compositions for treating infection | UNIVERSITY OF ROCHESTER (US) | 2018-06-26 | — | — | US | disclosed |
| US-10004701-B2 | Methods and compositions for treating infection | UNIVERSITY OF ROCHESTER (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170065540-A1 | METHODS AND COMPOSITIONS FOR TREATING INFECTION | UNIVERSITY OF ROCHESTER (US) | 2017-03-09 | — | — | US | disclosed |
| US-20170065540-A1 | METHODS AND COMPOSITIONS FOR TREATING INFECTION | UNIVERSITY OF ROCHESTER (US) | 2017-03-09 | — | — | US | disclosed |
| US-20170065540-A1 | METHODS AND COMPOSITIONS FOR TREATING INFECTION | UNIVERSITY OF ROCHESTER (US) | 2017-03-09 | — | — | US | disclosed |
| US-20150238473-A1 | METHODS AND COMPOSITIONS FOR TREATING INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-08-27 | — | — | US | disclosed |
| US-20150238473-A1 | METHODS AND COMPOSITIONS FOR TREATING INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-08-27 | — | — | US | disclosed |
| US-20150238473-A1 | METHODS AND COMPOSITIONS FOR TREATING INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-08-27 | — | — | US | disclosed |
| US-4328380-A | Substituted phenylpropyl halides | BASF AKTIENGESELLSCHAFT (DE) | 1982-05-04 | — | — | US | disclosed |
| EP-0009077-B1 | SUBSTITUTED PHENYLPROPYL HALIDES, THEIR PREPARATION AND USE | BASF Aktiengesellschaft (DE) | 1981-09-30 | — | — | EP | disclosed |
| US-4250123-A | CHEMICAL INTERMEDIATES FOR FUNGICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1981-02-10 | — | — | US | disclosed |
| EP-0009077-A1 | Substituted phenylpropyl halides, their preparation and use | BASF Aktiengesellschaft (DE) | 1980-04-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150238473-A1 | METHODS AND COMPOSITIONS FOR TREATING INFECTION | MMP8, IFNG, MPO | KCNH2 1413/4885SIGMAR1 4344/4885LMNA 1841/4885 |
| US-20170065540-A1 | METHODS AND COMPOSITIONS FOR TREATING INFECTION | MMP8, IFNG, MPO | KCNH2 1413/4885SIGMAR1 4344/4885LMNA 1841/4885 |
| US-10004701-B2 | Methods and compositions for treating infection | MMP8, IFNG, MPO | KCNH2 1413/4885SIGMAR1 4344/4885LMNA 1841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.